Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression

Abstract The PIKTAM study evaluated the efficacy and safety of the PI3K inhibitor buparlisib in combination with tamoxifen in hormone receptor‐positive (HR+), HER2‐negative advanced breast cancer patients after failure of prior endocrine therapy. In this open‐label, single‐arm phase II trial, 25 pat...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Anja Welt, Marcel Wiesweg, Sarah Theurer, Wolfgang Abenhardt, Matthias Groschek, Lothar Müller, Jan Schröder, Mitra Tewes, Marco Chiabudini, Karin Potthoff, Agnes Bankfalvi, Norbert Marschner, Martin Schuler, Frank Breitenbücher
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Wiley 2020-07-01
Cyfres:Cancer Medicine
Pynciau:
breast cancer
buparlisib
clinical trial
phase II
drug therapy
PI3K
Mynediad Ar-lein:https://doi.org/10.1002/cam4.3092

Rhyngrwyd

https://doi.org/10.1002/cam4.3092

Eitemau Tebyg